Health Care · Pharmaceuticals
Johnson & Johnson: revenue, profit and dividends
In fiscal 2025, Johnson & Johnson had revenue of $94.2B, up 3.0% a year on average since 2015, and net income of $26.8B (28.5% of revenue). Its dividend per share has gone up 18 years in a row, to $5.14. It has 14% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +6.0% vs 2024
- Ticker
- JNJ · NYSE
- Sector
- Health Care
- Sub-industry
- Pharmaceuticals
- Headquarters
- New Brunswick, New Jersey
- Founded
- 1886
- In the S&P 500 since
- June 30, 1973
- Latest fiscal year
- 2025, ended December 28, 2025
- SEC filer
- Johnson & Johnson · CIK 0000200406
Revenue and net income
Revenue went from $61.1B in 2007 to $94.2B in 2025.
Diluted earnings per share
Diluted EPS went from $3.63 in 2007 to $11.03 in 2025. Ten-year growth: 7.2% a year.
Dividends per share
Raised every year in the data: 18 years in a row, from 2008 to 2025. Ten-year growth: 5.7% a year.
Shares outstanding
13.6% fewer shares in 2025 than in 2015 (2.81B → 2.43B): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $19.7B in 2025, 20.9% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $94.2B | $26.8B | 28.5% | $11.03 | $5.14 | 2.43B | $24.5B | $4.83B | $19.7B |
| 2024 | $88.8B | $14.1B | 15.8% | $5.79 | $4.91 | 2.43B | $24.3B | $4.42B | $19.8B |
| 2023 | $85.2B | $35.2B | 41.3% | $13.72 | $4.70 | 2.56B | $22.8B | $4.54B | $18.2B |
| 2022 | $80B | $17.9B | 22.4% | $6.73 | $4.45 | 2.66B | $21.2B | $4.01B | $17.2B |
| 2021 | $78.7B | $20.9B | 26.5% | $7.81 | $4.19 | 2.67B | $23.4B | $3.65B | $19.8B |
| 2020 | $82.6B | $14.7B | 17.8% | $5.51 | $3.98 | 2.67B | $23.5B | $3.35B | $20.2B |
| 2019 | $82.1B | $15.1B | 18.4% | $5.63 | $3.75 | 2.68B | $23.4B | $3.5B | $19.9B |
| 2018 | $81.6B | $15.3B | 18.8% | $5.61 | $3.54 | 2.73B | $22.2B | $3.67B | $18.5B |
| 2017 | $76.5B | $1.3B | 1.7% | $0.47 | $3.32 | 2.75B | $21.1B | $3.28B | $17.8B |
| 2016 | $71.9B | $16.5B | 23.0% | $5.93 | $3.15 | 2.79B | $18.8B | $3.23B | $15.5B |
| 2015 | $70.1B | $15.4B | 22.0% | $5.48 | $2.95 | 2.81B | $19.6B | $3.46B | $16.1B |
| 2014 | $74.3B | $16.3B | 22.0% | $5.70 | $2.76 | 2.86B | $18.7B | $3.71B | $15B |
| 2013 | $71.3B | $13.8B | 19.4% | $4.81 | $2.59 | 2.88B | $17.4B | $3.6B | $13.8B |
| 2012 | $67.2B | $10.9B | 16.1% | $3.86 | $2.40 | 2.81B | $15.4B | $2.93B | $12.5B |
| 2011 | $65B | $9.67B | 14.9% | $3.49 | $2.25 | 2.78B | $14.3B | $2.89B | $11.4B |
| 2010 | $61.6B | $13.3B | 21.7% | $4.78 | $2.11 | 2.79B | $16.4B | $2.38B | $14B |
| 2009 | $61.9B | $12.3B | 19.8% | $4.40 | $1.93 | 2.79B | $16.6B | $2.37B | $14.2B |
| 2008 | $63.7B | $12.9B | 20.3% | $4.57 | $1.79 | 2.84B | $15B | $3.07B | $11.9B |
| 2007 | $61.1B | $10.6B | 17.3% | $3.63 | $1.62 | 2.91B | $15B | $2.94B | $12.1B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Pharmaceuticals companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.